By Counterforce Health Team in Zanzalintinib (XL092) [investigational] —

If Zanzalintinib (XL092) Isn't Approved by UnitedHealthcare in New Jersey: Formulary Alternatives & Exception Paths

Answer Box: Getting Zanzalintinib (XL092) Coverage in New Jersey

Zanzalintinib (XL092) is investigational and typically denied by UnitedHealthcare outside clinical trials. Your fastest path: (1) Check trial eligibility at ClinicalTrials.gov—patients with ≤2 prior TKIs may qualify; (2) If ineligible, request medical exception through OptumRx for compassionate use with strong clinical documentation; (3) If denied, file internal appeals within 180 days, then New Jersey's IHCAP external review within 4 months. Start with your oncologist submitting prior authorization today through the UHC provider portal.

Table of Contents

  1. When Alternatives Make Sense
  2. Typical Formulary Alternatives
  3. Pros and Cons Overview
  4. Exception Strategy for Zanzalintinib
  5. Switching Logistics
  6. Re-trying for Zanzalintinib Later
  7. Appeals Playbook for New Jersey
  8. FAQ

When Alternatives Make Sense

Since Zanzalintinib (XL092) remains investigational with no FDA approvals as of 2025, UnitedHealthcare typically covers it only within clinical trials or through compassionate use programs. Before pursuing complex exception requests, consider whether proven alternatives might be appropriate for your condition.

Clinical scenarios where alternatives are preferred:

  • You haven't tried standard-of-care TKIs yet
  • Your cancer type has established treatment pathways
  • You need immediate treatment (trials have screening delays)
  • Your performance status or organ function doesn't meet trial criteria

When to push for Zanzalintinib specifically:

  • You've failed ≤2 prior TKIs (meeting trial eligibility criteria)
  • Standard options are contraindicated due to cardiac, hepatic, or other toxicities
  • Your cancer subtype has limited approved options (e.g., non-clear cell RCC, certain sarcomas)
Note: Clinical trials for Zanzalintinib typically require ≥2 prior systemic therapies but ≤2 prior TKIs, making it suitable for patients who've progressed on standard care but aren't heavily pre-treated.

Typical Formulary Alternatives

UnitedHealthcare's formulary includes several multi-target TKIs that may be appropriate depending on your cancer type. Here's an educational overview of common alternatives:

Renal Cell Carcinoma (RCC)

Drug Targets Formulary Status Common Step Therapy
Cabozantinib (Cabometyx) VEGFR, MET, RET, AXL Tier 3-4 After sunitinib or pazopanib
Lenvatinib + Pembrolizumab VEGFR, FGFR, RET + PD-1 Tier 4 First-line or after TKI
Axitinib (Inlyta) VEGFR Tier 3 After cytokine therapy

Hepatocellular Carcinoma (HCC)

Drug Targets Formulary Status Common Step Therapy
Sorafenib (Nexavar) VEGFR, RAF, PDGFR Tier 3 First-line standard
Regorafenib (Stivarga) VEGFR, PDGFR, FGFR Tier 4 After sorafenib progression
Cabozantinib VEGFR, MET, RET Tier 4 Second-line option

Sarcomas

Drug Targets Formulary Status Common Step Therapy
Pazopanib (Votrient) VEGFR, PDGFR, c-KIT Tier 3 After anthracycline-based chemo
Regorafenib Multiple kinases Tier 4 After standard chemotherapy
Tip: Check your specific plan's formulary at myuhc.com under "Prescription Drug Coverage" to confirm tier placement and any quantity limits.

Pros and Cons Overview

Formulary Alternatives: Advantages

  • Faster access: No prior authorization delays for preferred drugs
  • Lower copays: Tier 2-3 drugs typically cost less than specialty tier
  • Established monitoring: Clear guidelines for lab work and dose adjustments
  • Insurance stability: Less likely to be removed from formulary mid-treatment

Formulary Alternatives: Considerations

  • Different side effect profile: May not tolerate alternatives if you had specific toxicities
  • Efficacy differences: Response rates vary by cancer subtype and prior treatments
  • Dosing complexity: Some combinations require more frequent monitoring
  • Step therapy requirements: May need to "fail" cheaper options first

Zanzalintinib Exception Path: Advantages

  • Novel mechanism: Multi-target profile may work when others haven't
  • Trial data access: Potential for compassionate use based on ongoing studies
  • Personalized approach: Tailored to your specific resistance patterns

Zanzalintinib Exception Path: Challenges

  • Complex approval process: Requires extensive documentation and appeals
  • Higher costs: Specialty tier copays ($200-500+ monthly)
  • Limited precedent: Fewer successful appeals for investigational drugs
  • Time-intensive: 3-6 months for full appeals process

Exception Strategy for Zanzalintinib

When formulary alternatives aren't appropriate, here's how to build the strongest case for Zanzalintinib coverage:

Step 1: Clinical Documentation

Your oncologist should compile:

  • Diagnosis with staging: ICD-10 codes and imaging showing progression
  • Prior therapy history: Dates, doses, duration, and specific reasons for discontinuation
  • Contraindications to alternatives: Cardiac function tests if cabozantinib contraindicated, liver function if sorafenib inappropriate
  • Performance status: ECOG score and functional assessment

Step 2: Literature Support

Include peer-reviewed evidence:

  • STELLAR program trial results showing activity in your cancer type
  • Mechanism of action studies explaining why Zanzalintinib's targets differ from failed therapies
  • Case reports or abstracts supporting off-label use (if any exist)

Step 3: Medical Exception Request

Submit through OptumRx specialty pharmacy:

  • Phone: 1-855-427-4682 (24/7 support)
  • Online: specialty.optumrx.com provider portal
  • Documentation: All clinical records, literature, and physician letter
From our advocates: We've seen the strongest exception approvals when physicians write detailed letters explaining not just why the patient needs Zanzalintinib, but specifically why each formulary alternative is inappropriate. Generic "patient needs this drug" letters rarely succeed, but point-by-point rebuttals of step therapy requirements often do.

Step 4: Compassionate Use Parallel Track

Contact Exelixis Medical Affairs directly:

  • Request expanded access program enrollment
  • Provide same clinical documentation
  • This can supplement insurance appeals with manufacturer support

Switching Logistics

If you decide to try a formulary alternative first:

Coordination Steps

  1. Washout period: Allow 14 days between TKIs to avoid drug interactions
  2. Baseline testing: Repeat imaging, labs, and cardiac function before switching
  3. Pharmacy coordination: Ensure new drug is in-network and available
  4. Monitoring plan: Schedule follow-up visits at 2, 4, and 8 weeks

Documentation for Future Appeals

Keep detailed records of your alternative therapy trial:

  • Response assessment: RECIST measurements at each scan
  • Toxicity log: Grade and duration of side effects
  • Quality of life: Functional status changes
  • Adherence data: Any dose reductions or treatment delays

This documentation strengthens future Zanzalintinib appeals by proving you gave alternatives a fair trial.

Re-trying for Zanzalintinib Later

When to Re-appeal

  • Disease progression: New scans showing growth on current therapy
  • Intolerable toxicity: Grade 3+ side effects requiring discontinuation
  • New trial data: Published results supporting Zanzalintinib in your situation
  • Policy changes: UnitedHealthcare updates coverage criteria

Strengthening Your Case

  • Document everything: Keep records of all treatments tried, responses, and failures
  • Stay current: Monitor ClinicalTrials.gov for new Zanzalintinib studies you might join
  • Build relationships: Maintain contact with your care team and specialty pharmacy
  • Consider timing: Re-appeal when you have new clinical information, not just because time has passed

Appeals Playbook for New Jersey

Internal Appeals (UnitedHealthcare)

Level 1 Appeal

  • Deadline: 180 days from denial date
  • How to file: UHC member portal, phone (1-866-889-8054), or mail
  • Timeline: 60 days for determination
  • Documents: Denial letter, medical records, physician letter, literature

Level 2 Appeal

  • Deadline: 60 days from Level 1 denial
  • Timeline: 30 days for determination
  • Enhancement: Request peer-to-peer review with UHC medical director

External Review (New Jersey IHCAP)

Eligibility: After exhausting internal appeals for NJ-regulated plans

Required Documents:

  • IHCAP application form
  • All denial letters
  • Complete medical records
  • Physician certification of medical necessity
  • Supporting literature

Expedited Appeals

For urgent cases where delay could jeopardize health:

  • Internal: 24-hour determination
  • External: 72-hour determination
  • Requirement: Physician certification of urgency
Note: Counterforce Health specializes in turning insurance denials into targeted appeals, helping patients navigate complex prior authorization requirements and evidence-backed rebuttals for specialty medications like investigational TKIs.

FAQ

How long does UnitedHealthcare prior authorization take in New Jersey? Standard PA decisions take up to 72 hours for non-urgent requests, 24 hours for expedited cases. Medical exceptions for investigational drugs can take up to 15 business days.

What if Zanzalintinib is completely non-formulary? Non-formulary drugs require medical exceptions through OptumRx. You'll need strong clinical justification and documentation of failed alternatives. Success rates are lower but possible with compelling cases.

Can I request an expedited appeal? Yes, if your physician certifies that delay would jeopardize your health. Both internal UHC appeals and New Jersey IHCAP external reviews have expedited tracks.

Does step therapy apply if I've failed TKIs outside New Jersey? Yes, prior therapy history from any state counts toward step therapy requirements. Provide complete treatment records including dates, doses, and reasons for discontinuation.

What counts as medical necessity for investigational drugs? Medical necessity requires showing the drug is appropriate for your condition, no equally effective alternatives exist, and there's substantial evidence of safety/efficacy from clinical trials or peer-reviewed literature.

How much does Zanzalintinib cost without insurance? As an investigational drug, Zanzalintinib doesn't have a U.S. list price. Clinical trial participation typically covers drug costs, while compassionate use programs may offer manufacturer support.

Can providers file external appeals on my behalf? Yes, New Jersey allows providers to file IHCAP appeals with patient consent. This can be helpful for complex cases requiring detailed medical documentation.

What if my plan is self-funded through my employer? Self-funded ERISA plans aren't eligible for New Jersey IHCAP external review. You'd need to pursue federal appeals processes or contact the Department of Labor for guidance.

When navigating coverage for investigational drugs like Zanzalintinib, having expert support can make the difference between approval and denial. Counterforce Health helps patients and clinicians turn insurance denials into successful appeals by analyzing denial letters, identifying the specific coverage criteria, and drafting evidence-backed rebuttals that address payers' own rules and requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and is not medical advice. Insurance coverage decisions depend on your specific plan terms, medical history, and clinical circumstances. Always consult your healthcare provider and insurance company for personalized guidance. Coverage policies change frequently—verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.